Table 2.

Gene dosage effects of GUCY1A3 rs7692387 risk (G) allele on incident cardiovascular disease among Physician’s Health Study men randomized to aspirin or placebo^a

Modela	Outcome	Cases/controls	Aspirin OR (95% CI)	P-value	Placebo OR (95% CI)	P-value	P interaction
Before 1988b	Major CVD	228/260	0.43 (0.17–1.04)	0.06	1.31 (0.66–2.61)	0.44	0.06
	MI	163/192	0.29 (0.09–1.00)	0.05	2.04 (0.91–4.54)	0.08	0.02
	Stroke	65/68	0.46 (0.10–2.23)	0.34	0.08 (0.00–1.26)	0.07	0.23
Through 1990	Major CVD	409/523	0.51 (0.28–0.92)	0.03	0.88 (0.52–1.51)	0.65	0.19
	MI	250/300	0.36 (0.15–0.88)	0.02	1.42 (0.72–2.77)	0.31	0.02
	Stroke	159/223	0.67 (0.28–1.59)	0.36	0.40 (0.14–1.12)	0.08	0.43

^aEstimates from conditional logistic regression gene dosage models including terms for additive genetic effect (on the log scale) of the ‘G’ risk allele, randomized drug allocation, and interaction between the genetic effect and drug allocation. The genetic effect in aspirin or placebo strata, respectively, was estimated by encoding drug allocation as 0 = placebo/1 = aspirin or 1 = placebo/0 = aspirin. Controls were matched on age and smoking history were used only once.

^bModels were adjusted for CVD risk factors: history of diabetes, cholesterol, BMI, systolic and diastolic blood pressure. Models: Before 1988 = white cases before 25 January 1988 when randomization to aspirin was terminated; through 1990 = all white cases and controls through 1990 when the trial ended.